in vitro pharmacology models in Cardiovascular diseases

The clot lysis assay evaluates the efficacy of your fibrinolytic candidates on human plasma pools. Performed by turbidimetry in 96-well plates, it provides rapid assessment of compounds activity through parameters such as the 50% clot lysis time (LT50). The high reproducibility of the assay ensures reliable and straightforward comparison of dose-response curves throughout lead-optimisation phases.

This assay also allows investigation of compound interactions when combined with reference fibrinolytics (Alteplase, Tenecteplase).

The ROTEM assay, performed on fresh human whole blood, measures the viscoelastic properties of the clot throughout its formation and subsequent lysis. A wide range of parameters can be extracted from the thromboelastogram, including the clotting time, the maximum clot firmness, and the 50% clot lysis time (LT50). This low-throughput assay offers an extensive and customisable set of hemostatic conditions for evaluating anticoagulant or thrombolytic compounds, including extrinsic or intrinsic activation pathways, as well as the addition of coagulation factors or modulators.

This assay also allows investigation of compound interactions when combined with reference fibrinolytics (Alteplase, Tenecteplase).

Documenting potential interactions between reference fibrinolytics and drug candidates is required by regulatory agencies when these treatments are intended for combined administration during the acute phase of stroke.

Using turbidimetry in 96-well plates, the clot lysis assay quantifies fibrinolytic activity in human plasma pools, relying on parameters such as the 50% clot lysis time (LT50). The high reproducibility of the assay ensures reliable and straightforward comparison of dose-response curves for Alteplase or Tenecteplase, either alone or in combination with multiple concentrations of your compound.

This assay also allows investigation of compound interactions when combined with reference fibrinolytics (Alteplase, Tenecteplase).

The ROTEM assay, performed on fresh human whole blood, measures the viscoelastic properties of the clot throughout its formation and subsequent lysis.

A wide range of parameters can be extracted from the thromboelastogram, including the clotting time, the maximum clot firmness, and the 50% clot lysis time (LT50). This low-throughput assay offers an extensive and customisable set of hemostatic conditions for evaluating anticoagulant or thrombolytic compounds, including extrinsic or intrinsic activation pathways, as well as the addition of coagulation factors or modulators.